<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with IBD are not included in this high-risk group, and their potential for hepatitis A exposure might not different from those without IBD. However, they are often treated with immunomodulators and biologics for long periods, as single agents or in combination, and pre-exposure protection (vaccination) is recommended in immunocompromised patients, as well as in those with chronic liver disease [
 <xref rid="b21-ir-2019-09155" ref-type="bibr">21</xref>].
</p>
